Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Immatics Biotechnologies GmbH - Product Pipeline Review - 2015

Published: Feb-2015 | Format: PDF | Global Markets Direct | Number of pages: 33 | Code: MRS - 7042

 

Global Markets Direct’s, ‘immatics biotechnologies GmbH Product Pipeline Review 2015’, provides an overview of the immatics biotechnologies GmbH’s pharmaceutical research and development focus.

 

This report provides comprehensive information on the current therapeutic developmental pipeline of immatics biotechnologies GmbH’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

 

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

 

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

 

Scope

 

The report provides brief overview of immatics biotechnologies GmbH including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of immatics biotechnologies GmbH’s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement 
Latest news and deals relating to the immatics biotechnologies GmbH’s pipeline products

 

Reasons to buy

 

Evaluate immatics biotechnologies GmbH’s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of immatics biotechnologies GmbH in its therapy areas of focus
Identify new drug targets and therapeutic classes in the immatics biotechnologies GmbH’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of immatics biotechnologies GmbH and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of immatics biotechnologies GmbH
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of immatics biotechnologies GmbH and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues

Table of Contents
 

 

Table of Contents 2
List of Tables 3
List of Figures 3
immatics biotechnologies GmbH Snapshot 4
immatics biotechnologies GmbH Overview 4
Key Information 4
Key Facts 4
immatics biotechnologies GmbH - Research and Development Overview 5
Key Therapeutic Areas 5
immatics biotechnologies GmbH - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
immatics biotechnologies GmbH - Pipeline Products Glance 11
immatics biotechnologies GmbH - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
immatics biotechnologies GmbH - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
immatics biotechnologies GmbH - Drug Profiles 14
IMA-901 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
IMA-910 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
APVAC-1 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
APVAC-2 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IMA-950 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
immatics biotechnologies GmbH - Pipeline Analysis 24
immatics biotechnologies GmbH - Pipeline Products by Target 24
immatics biotechnologies GmbH - Pipeline Products by Route of Administration 25
immatics biotechnologies GmbH - Pipeline Products by Molecule Type 26
immatics biotechnologies GmbH - Recent Pipeline Updates 27
immatics biotechnologies GmbH - Company Statement 30
immatics biotechnologies GmbH - Locations And Subsidiaries 31
Head Office 31

 

Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33


List of Tables
 

immatics biotechnologies GmbH, Key Information 4
immatics biotechnologies GmbH, Key Facts 4
immatics biotechnologies GmbH - Pipeline by Indication, 2015 6
immatics biotechnologies GmbH - Pipeline by Stage of Development, 2015 7
immatics biotechnologies GmbH - Monotherapy Products in Pipeline, 2015 8
immatics biotechnologies GmbH - Out-Licensed Products in Pipeline, 2015 9
immatics biotechnologies GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2015 10
immatics biotechnologies GmbH - Phase III, 2015 11
immatics biotechnologies GmbH - Phase II, 2015 12
immatics biotechnologies GmbH - Phase I, 2015 13
immatics biotechnologies GmbH - Pipeline by Target, 2015 24
immatics biotechnologies GmbH - Pipeline by Route of Administration, 2015 25
immatics biotechnologies GmbH - Pipeline by Molecule Type, 2015 26
immatics biotechnologies GmbH - Recent Pipeline Updates, 2015 27


List of Figures
 

immatics biotechnologies GmbH - Pipeline by Top 10 Indication, 2015 6
immatics biotechnologies GmbH - Pipeline by Stage of Development, 2015 7
immatics biotechnologies GmbH - Monotherapy Products in Pipeline, 2015 8
immatics biotechnologies GmbH - Pipeline by Top 10 Route of Administration, 2015 25
immatics biotechnologies GmbH - Pipeline by Top 10 Molecule Type, 2015 26

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)1500 View Pricing